title: Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.
abstract: Background Multiple studies have compared the efficacy of entecavir with lamivudine in preventing hepatitis B virus (HBV) reactivation among HBV-carrying lymphoma patients with chemotherapy treatment. However, the results were slightly varied. Aim of the review to combine the findings of independent studies assessing the clinical efficacy of the two drugs using a systematic review and meta-analysis. Methods PubMed, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chongqing VIP and WanFang Data were retrieved. Two independent reviewers evaluated the study eligibility and extracted eight studies, with 770 patients in total. The meta-analysis was conducted using RevMan 5.3 and STATA software. Results HBV-carrying lymphoma patients receiving lamivudine during chemotherapy had a statistically significantly higher odds of HBV reactivation compared to those receiving entecavir (OR 5.0, 95 % CI 2.85-8.78, P < 0.001). The odds of hepatitis, HBV-Reactivation caused hepatitis and chemotherapy disruption was statistically significantly elevated in the patient group receiving lamivudine compared to the entecavir group (OR 4.12, 95 % CI 1.70-9.98, P = 0.002; OR 11.44, 95 % CI 2.70-48.52, P < 0.001; OR 6.71, 95 % CI 2.34-19.26, P < 0.001, respectively). Furthermore, the HBV reactivation rate in Ann Arbor stages I - II patient group was statistically significantly lower than the one in Ann Arbor stages III-IV group, with an overall pooled value of 0.37 (95 % CI 0.17-0.82, P = 0.01). Conclusion The metaanalysis result suggested that among HBV-carrying lymphoma patients undergoing chemotherapy, entecavir is more effective than lamivudine in preventing HBV reactivation.
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital and Institute, No 55, Sect. 4, South People's Road, Chengdu, 610041, Sichuan, People's Republic of China.
authors.forename: Sisi
authors.initials: S
authors.lastname: Yu
authors.affiliation: Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, People's Republic of China.
authors.forename: Huaichao
authors.initials: H
authors.lastname: Luo
authors.affiliation: Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, USA.
authors.forename: Meiling
authors.initials: M
authors.lastname: Pan
authors.affiliation: McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, USA.
authors.forename: Angel Palomino
authors.initials: AP
authors.lastname: Luis
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital and Institute, No 55, Sect. 4, South People's Road, Chengdu, 610041, Sichuan, People's Republic of China.
authors.forename: Zhujuan
authors.initials: Z
authors.lastname: Xiong
authors.affiliation: Health Management Center, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, People's Republic of China.
authors.forename: Pin
authors.initials: P
authors.lastname: Shuai
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital and Institute, No 55, Sect. 4, South People's Road, Chengdu, 610041, Sichuan, People's Republic of China. 304018651@qq.com.
authors.forename: Zhihui
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy / Q000453:epidemiology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine; C413685:entecavir; D006147:Guanine
keywords: Entecavir; Lamivudine; Lymphoma; Meta-analysis; Review